propranolol has been researched along with Breast Neoplasms in 39 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Propranolol regulates angiogenesis in pre-clinical models and reduces distant breast cancer (BC) metastases in observational studies." | 9.41 | Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer. ( Accordino, M; Crew, KD; Hershman, DL; Hopson, MB; Kalinsky, K; Lee, S; Maurer, M; Trivedi, M, 2021) |
| "Preclinical studies have demonstrated that propranolol inhibits several pathways involved in breast cancer progression and metastasis." | 8.93 | Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts. ( Bennett, K; Brown, C; Cardwell, CR; Cronin-Fenton, D; De Schutter, H; Friis, S; Garmo, H; Gavin, A; Lambe, M; Murray, LJ; O'Rorke, M; Pottegård, A; Powe, DG; Sharp, L; Vaes, E; van Herk-Sukel, MP; Vissers, PA; Visvanathan, K, 2016) |
| "Presurgical propranolol modulates biomarkers associated with breast cancer progression." | 7.96 | Propranolol: What is BLOCKing Its Clinical Investigation in Breast Cancer? ( Blaes, AH; Domingo-Musibay, E; Kalinsky, K, 2020) |
| "In this study, we measured changes in tumor proliferation and apoptosis in a late stage breast cancer patient treated with neoadjuvant propranolol." | 7.91 | The beta adrenergic receptor antagonist propranolol alters mitogenic and apoptotic signaling in late stage breast cancer. ( Aguilera, R; Bryan, B; Dickerson, E; Montoya, A; Nahleh, Z; Pasquier, E; Torabi, A; Varela-Ramirez, A, 2019) |
| "In this work, we evaluated the antitumor effect of metronomic treatment with a combination of two repositioned drugs, metformin and propranolol, in triple negative breast cancer models." | 7.85 | Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models. ( André, N; Baglioni, M; Bondarenko, M; Carré, M; Laluce, NC; Menacho Márquez, M; Rico, M; Rozados, V; Scharovsky, OG, 2017) |
| "In 2008, propranolol was serendipitously observed to cause accelerated involution of infantile haemangioma." | 7.77 | Low-dose propranolol for infantile haemangioma. ( Itinteang, T; Leadbitter, P; Tan, ST, 2011) |
| "Recent clinical evidence revealed that the use of beta-blockers such as propranolol, prior to diagnosis or concurrently with chemotherapy, could increase relapse-free and overall survival in breast cancer patients." | 7.77 | Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. ( André, N; Carre, M; Ciccolini, J; Fanciullino, R; Giacometti, S; Kavallaris, M; Montero, MP; Pasquier, E; Pouchy, C; Serdjebi, C, 2011) |
| "Globally breast cancer accounts for 24." | 5.91 | The Beta2-adrenergic agonist salbutamol synergizes with paclitaxel on cell proliferation and tumor growth in triple negative breast cancer models. ( Bruque, CD; Bruzzone, A; Jabloñski, M; Lüthy, IA; Pérez Piñero, C; Rivero, EM; Rodríguez, MS; Vanzulli, S, 2023) |
| " The treatment agreed during the interdisciplinary meeting involved chemotherapy combined with simultaneous blockade of beta-adrenergic receptors, followed by bilateral simple mastectomy." | 5.62 | Primary bilateral angiosarcoma of the breast treated with neoadjuvant chemotherapy combined with propranolol. ( Gorski, M; Hodorowicz-Zaniewska, D; Kargol, J; Luczynska, E; Popiela, TJ; Rudnicki, W; Szpor, J; Wysocki, PJ, 2021) |
| "Propranolol regulates angiogenesis in pre-clinical models and reduces distant breast cancer (BC) metastases in observational studies." | 5.41 | Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer. ( Accordino, M; Crew, KD; Hershman, DL; Hopson, MB; Kalinsky, K; Lee, S; Maurer, M; Trivedi, M, 2021) |
| "The advancement of breast cancer therapy is limited by the biologic behaviors of cancer cells, such as metastasis and recurrence." | 5.40 | Propranolol inhibits glucose metabolism and 18F-FDG uptake of breast cancer through posttranscriptional downregulation of hexokinase-2. ( Chen, X; Kang, F; Li, L; Ma, W; Ma, X; Shao, Y; Wang, J; Yang, W, 2014) |
| " Here, in a phase-II biomarker clinical trial in breast cancer patients (n = 38), we tested the combined perioperative use of the β-blocker, propranolol, and the COX2-inhibitor, etodolac, scheduled for 11 consecutive perioperative days, starting 5 days before surgery." | 5.27 | Perioperative inhibition of β-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome. ( Allweis, T; Barshack, I; Ben-Eliyahu, S; Birnbaum, Y; Cole, S; Haldar, R; Lavon, H; Lyons, YA; Shaashua, L; Sharon, E; Sood, AK; Zmora, O, 2018) |
| " In this study, to our knowledge, we present the first report of the effects of perioperative propranolol and/or parecoxib on peripheral regulatory T cells (Tregs) in breast cancer patients." | 5.22 | Propranolol Attenuates Surgical Stress-Induced Elevation of the Regulatory T Cell Response in Patients Undergoing Radical Mastectomy. ( Chen, G; Li, X; Li, Y; Liang, H; Ouyang, W; Tong, J; Wu, Y; Zhou, L, 2016) |
| "Preclinical studies have demonstrated that propranolol inhibits several pathways involved in breast cancer progression and metastasis." | 4.93 | Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts. ( Bennett, K; Brown, C; Cardwell, CR; Cronin-Fenton, D; De Schutter, H; Friis, S; Garmo, H; Gavin, A; Lambe, M; Murray, LJ; O'Rorke, M; Pottegård, A; Powe, DG; Sharp, L; Vaes, E; van Herk-Sukel, MP; Vissers, PA; Visvanathan, K, 2016) |
| "Presurgical propranolol modulates biomarkers associated with breast cancer progression." | 3.96 | Propranolol: What is BLOCKing Its Clinical Investigation in Breast Cancer? ( Blaes, AH; Domingo-Musibay, E; Kalinsky, K, 2020) |
| " It is conceivable that these effects are related to tumorigenesis, bringing a new perspective to understand the claimed anticancer effects of propranolol and the increase in breast cancer incidence caused by stress or during perimenopause." | 3.96 | β-Adrenoceptor Activation in Breast MCF-10A Cells Induces a Pattern of Catecholamine Production Similar to that of Tumorigenic MCF-7 Cells. ( Amaro, F; Fresco, P; Gonçalves, J; Oliveira, JC; Quintas, C; Reguengo, H; Silva, D; Vale, N, 2020) |
| "In this study, we measured changes in tumor proliferation and apoptosis in a late stage breast cancer patient treated with neoadjuvant propranolol." | 3.91 | The beta adrenergic receptor antagonist propranolol alters mitogenic and apoptotic signaling in late stage breast cancer. ( Aguilera, R; Bryan, B; Dickerson, E; Montoya, A; Nahleh, Z; Pasquier, E; Torabi, A; Varela-Ramirez, A, 2019) |
| "In this work, we evaluated the antitumor effect of metronomic treatment with a combination of two repositioned drugs, metformin and propranolol, in triple negative breast cancer models." | 3.85 | Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models. ( André, N; Baglioni, M; Bondarenko, M; Carré, M; Laluce, NC; Menacho Márquez, M; Rico, M; Rozados, V; Scharovsky, OG, 2017) |
| "Propranolol could provide palliative effects in progression and survival of breast cancer that are mainly mediated via direct immunomodulatory and apoptotic mechanisms and probably associated with indirect anti-angiogenic activity." | 3.80 | Effect of propranolol on IL-10, visfatin, Hsp70, iNOS, TLR2, and survivin in amelioration of tumor progression and survival in Solid Ehrlich Carcinoma-bearing mice. ( Abdin, AA; Saied, EM; Soliman, NA, 2014) |
| "The strongest cytotoxic effect was observed with propranolol suggesting that, in clinical practice, this pharmaceutical can be used in patients with breast cancer who have hypertension." | 3.78 | A retrospective in vitro study of the impact of anti-diabetics and cardioselective pharmaceuticals on breast cancer. ( Briese, V; Richter, C; Richter, DU; Szewczyk, M, 2012) |
| "In 2008, propranolol was serendipitously observed to cause accelerated involution of infantile haemangioma." | 3.77 | Low-dose propranolol for infantile haemangioma. ( Itinteang, T; Leadbitter, P; Tan, ST, 2011) |
| "Recent clinical evidence revealed that the use of beta-blockers such as propranolol, prior to diagnosis or concurrently with chemotherapy, could increase relapse-free and overall survival in breast cancer patients." | 3.77 | Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. ( André, N; Carre, M; Ciccolini, J; Fanciullino, R; Giacometti, S; Kavallaris, M; Montero, MP; Pasquier, E; Pouchy, C; Serdjebi, C, 2011) |
| "Within the realm of breast cancer, significant advances in therapy have led to improved survival outcomes, yet there is room for improvement." | 2.61 | Beta blockade as adjunctive breast cancer therapy: A review. ( Clamon, G; Phadke, S, 2019) |
| "Globally breast cancer accounts for 24." | 1.91 | The Beta2-adrenergic agonist salbutamol synergizes with paclitaxel on cell proliferation and tumor growth in triple negative breast cancer models. ( Bruque, CD; Bruzzone, A; Jabloñski, M; Lüthy, IA; Pérez Piñero, C; Rivero, EM; Rodríguez, MS; Vanzulli, S, 2023) |
| " The treatment agreed during the interdisciplinary meeting involved chemotherapy combined with simultaneous blockade of beta-adrenergic receptors, followed by bilateral simple mastectomy." | 1.62 | Primary bilateral angiosarcoma of the breast treated with neoadjuvant chemotherapy combined with propranolol. ( Gorski, M; Hodorowicz-Zaniewska, D; Kargol, J; Luczynska, E; Popiela, TJ; Rudnicki, W; Szpor, J; Wysocki, PJ, 2021) |
| "Metastasis is the main cause of these deaths." | 1.46 | The β 2-Adrenergic Agonist Salbutamol Inhibits Migration, Invasion and Metastasis of the Human Breast Cancer MDA-MB- 231 Cell Line. ( Bruzzone, A; Entschladen, F; Gargiulo, L; Lüthy, IA; Piñero, CP; Rivero, EM; Zänker, K, 2017) |
| "The proliferation of prostate and breast cancer cells, but not of non-tumorigenic cells, was repressed upon lipin-1 knock-down." | 1.42 | Lipin-1 regulates cancer cell phenotype and is a potential target to potentiate rapamycin treatment. ( Arnould, T; Brohée, L; Colige, AC; Demine, S; Deroanne, CF; Willems, J, 2015) |
| "Furthermore, we report that breast cancer cell migration is decreased by the FDA-approved β-blocker, propranolol." | 1.42 | β-Adrenergic receptors suppress Rap1B prenylation and promote the metastatic phenotype in breast cancer cells. ( Lorimer, E; Tyburski, MD; Williams, CL; Wilson, JM, 2015) |
| "We found that breast cancer is related to age greater than 50 (P ≤ 0." | 1.42 | Evaluation of the Effect of 1,3-Bis(4-Phenyl)-1H-1,2,3-Triazolyl-2-Propanolol on Gene Expression Levels of JAK2-STAT3, NF-κB, and SOCS3 in Cells Cultured from Biopsies of Mammary Lesions. ( Bañales, JM; Becerril, JL; Benítez, JG; Juárez, JJ; Navarro, MD; Zerón, HM, 2015) |
| "As a result, SSRIinduced akathisia is very frequently under-recognized." | 1.40 | A case of akathisia induced by escitalopram: case report & review of literature. ( Basu, B; De, S; Dutta, N; Gangopadhyay, T; Mandal, B; Mondal, S, 2014) |
| "The advancement of breast cancer therapy is limited by the biologic behaviors of cancer cells, such as metastasis and recurrence." | 1.40 | Propranolol inhibits glucose metabolism and 18F-FDG uptake of breast cancer through posttranscriptional downregulation of hexokinase-2. ( Chen, X; Kang, F; Li, L; Ma, W; Ma, X; Shao, Y; Wang, J; Yang, W, 2014) |
| "Propranolol users were significantly less likely to present with a T4 (odds ratio [OR], 0." | 1.37 | Beta blockers and breast cancer mortality: a population- based study. ( Barron, TI; Bennett, K; Connolly, RM; Sharp, L; Visvanathan, K, 2011) |
| "GIRK4 was expressed in all six breast cancer cell lines, and GIRK2 was expressed in all but ZR-75-1 and MDA-MB-435." | 1.32 | Expression of inwardly rectifying potassium channels (GIRKs) and beta-adrenergic regulation of breast cancer cell lines. ( Cakir, Y; Plummer, HK; Schuller, HM; Yu, Q, 2004) |
| "Two case reports are described, both breast carcinoma patients with metastatic disease." | 1.27 | A call for caution in the use of aminoglutethimide: negative interactions with dexamethasone and beta blocker treatment. ( Baerwald, H; Catane, R; Halpern, J, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (7.69) | 18.7374 |
| 1990's | 1 (2.56) | 18.2507 |
| 2000's | 2 (5.13) | 29.6817 |
| 2010's | 27 (69.23) | 24.3611 |
| 2020's | 6 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Yee, EM | 1 |
| Pasquier, E | 3 |
| Iskander, G | 1 |
| Wood, K | 1 |
| Black, DS | 1 |
| Kumar, N | 1 |
| Gales, L | 1 |
| Forsea, L | 1 |
| Mitrea, D | 1 |
| Stefanica, I | 1 |
| Stanculescu, I | 1 |
| Mitrica, R | 1 |
| Georgescu, M | 1 |
| Trifanescu, O | 1 |
| Anghel, R | 1 |
| Serbanescu, L | 1 |
| Jabloñski, M | 1 |
| Rodríguez, MS | 1 |
| Rivero, EM | 2 |
| Bruque, CD | 1 |
| Vanzulli, S | 1 |
| Bruzzone, A | 3 |
| Pérez Piñero, C | 2 |
| Lüthy, IA | 4 |
| Montoya, A | 2 |
| Varela-Ramirez, A | 1 |
| Dickerson, E | 1 |
| Torabi, A | 2 |
| Aguilera, R | 1 |
| Nahleh, Z | 2 |
| Bryan, B | 1 |
| Blaes, AH | 1 |
| Domingo-Musibay, E | 1 |
| Kalinsky, K | 2 |
| Amaro, F | 1 |
| Silva, D | 1 |
| Reguengo, H | 1 |
| Oliveira, JC | 1 |
| Quintas, C | 1 |
| Vale, N | 1 |
| Gonçalves, J | 1 |
| Fresco, P | 1 |
| Hopson, MB | 1 |
| Lee, S | 1 |
| Accordino, M | 1 |
| Trivedi, M | 1 |
| Maurer, M | 1 |
| Crew, KD | 1 |
| Hershman, DL | 1 |
| Luczynska, E | 1 |
| Rudnicki, W | 1 |
| Kargol, J | 1 |
| Szpor, J | 1 |
| Hodorowicz-Zaniewska, D | 1 |
| Wysocki, PJ | 1 |
| Gorski, M | 1 |
| Popiela, TJ | 1 |
| Piñero, CP | 1 |
| Gargiulo, L | 1 |
| Entschladen, F | 2 |
| Zänker, K | 1 |
| Ashrafi, S | 2 |
| Shapouri, R | 2 |
| Shirkhani, A | 1 |
| Mahdavi, M | 2 |
| Haldar, R | 1 |
| Shaashua, L | 1 |
| Lavon, H | 1 |
| Lyons, YA | 1 |
| Zmora, O | 1 |
| Sharon, E | 1 |
| Birnbaum, Y | 1 |
| Allweis, T | 1 |
| Sood, AK | 1 |
| Barshack, I | 1 |
| Cole, S | 1 |
| Ben-Eliyahu, S | 1 |
| Phadke, S | 1 |
| Clamon, G | 1 |
| Kang, F | 1 |
| Ma, W | 1 |
| Ma, X | 1 |
| Shao, Y | 1 |
| Yang, W | 1 |
| Chen, X | 1 |
| Li, L | 1 |
| Wang, J | 1 |
| Basu, B | 1 |
| Gangopadhyay, T | 1 |
| Dutta, N | 1 |
| Mandal, B | 1 |
| De, S | 1 |
| Mondal, S | 1 |
| Abdin, AA | 1 |
| Soliman, NA | 1 |
| Saied, EM | 1 |
| Brohée, L | 1 |
| Demine, S | 1 |
| Willems, J | 1 |
| Arnould, T | 1 |
| Colige, AC | 1 |
| Deroanne, CF | 1 |
| Wilson, JM | 1 |
| Lorimer, E | 1 |
| Tyburski, MD | 1 |
| Williams, CL | 1 |
| Becerril, JL | 1 |
| Benítez, JG | 1 |
| Juárez, JJ | 1 |
| Bañales, JM | 1 |
| Zerón, HM | 1 |
| Navarro, MD | 1 |
| Zhou, L | 1 |
| Li, Y | 1 |
| Li, X | 1 |
| Chen, G | 1 |
| Liang, H | 1 |
| Wu, Y | 1 |
| Tong, J | 1 |
| Ouyang, W | 1 |
| Cardwell, CR | 1 |
| Pottegård, A | 1 |
| Vaes, E | 1 |
| Garmo, H | 1 |
| Murray, LJ | 1 |
| Brown, C | 1 |
| Vissers, PA | 1 |
| O'Rorke, M | 1 |
| Visvanathan, K | 2 |
| Cronin-Fenton, D | 1 |
| De Schutter, H | 1 |
| Lambe, M | 1 |
| Powe, DG | 2 |
| van Herk-Sukel, MP | 1 |
| Gavin, A | 1 |
| Friis, S | 1 |
| Sharp, L | 2 |
| Bennett, K | 2 |
| Rico, M | 1 |
| Baglioni, M | 1 |
| Bondarenko, M | 1 |
| Laluce, NC | 1 |
| Rozados, V | 1 |
| André, N | 2 |
| Carré, M | 2 |
| Scharovsky, OG | 1 |
| Menacho Márquez, M | 1 |
| Amaya, CN | 1 |
| Belmont, A | 1 |
| Diab, N | 1 |
| Trevino, R | 1 |
| Villanueva, G | 1 |
| Rains, S | 1 |
| Sanchez, LA | 1 |
| Badri, N | 1 |
| Otoukesh, S | 1 |
| Khammanivong, A | 1 |
| Liss, D | 1 |
| Baca, ST | 1 |
| Aguilera, RJ | 1 |
| Dickerson, EB | 1 |
| Dwivedi, AK | 1 |
| Abbas, A | 1 |
| Chambers, K | 1 |
| Bryan, BA | 1 |
| Friedman, GD | 1 |
| Udaltsova, N | 1 |
| Habel, LA | 1 |
| Tan, ST | 1 |
| Itinteang, T | 1 |
| Leadbitter, P | 1 |
| Schuller, HM | 2 |
| Ganz, PA | 1 |
| Cole, SW | 1 |
| Barron, TI | 1 |
| Connolly, RM | 1 |
| Ciccolini, J | 1 |
| Giacometti, S | 1 |
| Fanciullino, R | 1 |
| Pouchy, C | 1 |
| Montero, MP | 1 |
| Serdjebi, C | 1 |
| Kavallaris, M | 1 |
| Sarappa, MG | 1 |
| Castillo, LF | 1 |
| Strell, C | 1 |
| Niggemann, B | 1 |
| Voss, MJ | 1 |
| Zänker, KS | 1 |
| De Giorgi, V | 1 |
| Gandini, S | 1 |
| Grazzini, M | 1 |
| Benemei, S | 1 |
| Marchionni, N | 1 |
| Geppetti, P | 1 |
| Szewczyk, M | 1 |
| Richter, C | 1 |
| Briese, V | 1 |
| Richter, DU | 1 |
| Plummer, HK | 1 |
| Yu, Q | 1 |
| Cakir, Y | 1 |
| Halpern, J | 1 |
| Catane, R | 1 |
| Baerwald, H | 1 |
| Vázquez, SM | 1 |
| Pignataro, O | 1 |
| Finney, RE | 1 |
| Nudelman, E | 1 |
| White, T | 1 |
| Bursten, S | 1 |
| Klein, P | 1 |
| Leer, LL | 1 |
| Wang, N | 1 |
| Waggoner, D | 1 |
| Singer, JW | 1 |
| Lewis, RA | 1 |
| Wetterberg, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Perioperative Use of a β-adrenergic Blocker, Propranolol, and a COX2 Inhibitor, Etodolac, in Patients Undergoing Resection With Curative Intent for Primary Colon and Rectal Cancer: Effect on Tumor Recurrence and Survival[NCT03919461] | Phase 2 | 200 participants (Anticipated) | Interventional | 2019-02-28 | Recruiting | ||
| Perioperative Use of a Beta-adrenergic Blocker and a COX-2 Inhibitor in Patients Undergoing Surgery With Primary Pancreatic Cancer: Intervention Aiming to Reduce Pro-metastatic Processes[NCT03838029] | Phase 2 | 210 participants (Anticipated) | Interventional | 2019-11-20 | Recruiting | ||
| Melablock: A Multicentre Randomized, Double---blinded and Placebo---controlled Clinical Trial on the Efficacy and Safety of Once Daily Propranolol 80 mg Retard for the Prevention of Cutaneous Malignant Melanoma Recurrence[NCT02962947] | Phase 2/Phase 3 | 546 participants (Anticipated) | Interventional | 2017-06-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for propranolol and Breast Neoplasms
| Article | Year |
|---|---|
Antidiabetics, Anthelmintics, Statins, and Beta-Blockers as Co-Adjuvant Drugs in Cancer Therapy.
Topics: Adenosine Monophosphate; Adrenergic beta-Antagonists; Anthelmintics; Anti-Bacterial Agents; Antihype | 2022 |
Beta blockade as adjunctive breast cancer therapy: A review.
Topics: Adrenergic beta-Antagonists; Animals; Breast Neoplasms; Female; Humans; Propranolol | 2019 |
Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts.
Topics: Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Breast Neoplasms; Cohort Studies; Europe; Fema | 2016 |
Use of non-selective β-blockers is associated with decreased tumor proliferative indices in early stage breast cancer.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Apoptosis Regulatory Proteins; Breast Neoplasms; Cell Line | 2017 |
3 trials available for propranolol and Breast Neoplasms
| Article | Year |
|---|---|
Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Feasibility Stud | 2021 |
Perioperative inhibition of β-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Biomarkers; Breast Neoplasms; Cell Line, Tumor; Cyclooxyge | 2018 |
Perioperative inhibition of β-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Biomarkers; Breast Neoplasms; Cell Line, Tumor; Cyclooxyge | 2018 |
Perioperative inhibition of β-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Biomarkers; Breast Neoplasms; Cell Line, Tumor; Cyclooxyge | 2018 |
Perioperative inhibition of β-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Biomarkers; Breast Neoplasms; Cell Line, Tumor; Cyclooxyge | 2018 |
Propranolol Attenuates Surgical Stress-Induced Elevation of the Regulatory T Cell Response in Patients Undergoing Radical Mastectomy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Breast Neoplasms; Catecholamines; Cell Proliferation; Cell | 2016 |
32 other studies available for propranolol and Breast Neoplasms
| Article | Year |
|---|---|
Synthesis of novel isoflavene-propranolol hybrids as anti-tumor agents.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell | 2013 |
The Beta2-adrenergic agonist salbutamol synergizes with paclitaxel on cell proliferation and tumor growth in triple negative breast cancer models.
Topics: Adrenergic Agonists; Albuterol; Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Prolife | 2023 |
The beta adrenergic receptor antagonist propranolol alters mitogenic and apoptotic signaling in late stage breast cancer.
Topics: Adrenergic beta-Antagonists; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Huma | 2019 |
Propranolol: What is BLOCKing Its Clinical Investigation in Breast Cancer?
Topics: Biomarkers; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Epithelial-Mesenchymal Transitio | 2020 |
β-Adrenoceptor Activation in Breast MCF-10A Cells Induces a Pattern of Catecholamine Production Similar to that of Tumorigenic MCF-7 Cells.
Topics: Adrenergic Agonists; Breast; Breast Neoplasms; Catecholamines; Cell Line; Cell Proliferation; Cell S | 2020 |
Primary bilateral angiosarcoma of the breast treated with neoadjuvant chemotherapy combined with propranolol.
Topics: Breast Neoplasms; Female; Hemangiosarcoma; Humans; Mastectomy; Neoadjuvant Therapy; Propranolol | 2021 |
The β 2-Adrenergic Agonist Salbutamol Inhibits Migration, Invasion and Metastasis of the Human Breast Cancer MDA-MB- 231 Cell Line.
Topics: Adrenergic Agonists; Albuterol; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Pro | 2017 |
Anti-tumor effects of propranolol: Adjuvant activity on a transplanted murine breast cancer model.
Topics: Adjuvants, Immunologic; Adjuvants, Pharmaceutic; Animals; Antineoplastic Agents; Breast Neoplasms; C | 2018 |
Propranolol inhibits glucose metabolism and 18F-FDG uptake of breast cancer through posttranscriptional downregulation of hexokinase-2.
Topics: Animals; Biological Transport; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Female; Fluorode | 2014 |
A case of akathisia induced by escitalopram: case report & review of literature.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Second-Generation; Breast Neoplasms; Citalopram; | 2014 |
Effect of propranolol on IL-10, visfatin, Hsp70, iNOS, TLR2, and survivin in amelioration of tumor progression and survival in Solid Ehrlich Carcinoma-bearing mice.
Topics: Adrenergic beta-Antagonists; Animals; Apoptosis; Breast Neoplasms; Carcinoma, Ehrlich Tumor; Disease | 2014 |
Lipin-1 regulates cancer cell phenotype and is a potential target to potentiate rapamycin treatment.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; B | 2015 |
β-Adrenergic receptors suppress Rap1B prenylation and promote the metastatic phenotype in breast cancer cells.
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Antagonists; Aminopyridines; Breast Neoplasms; | 2015 |
Evaluation of the Effect of 1,3-Bis(4-Phenyl)-1H-1,2,3-Triazolyl-2-Propanolol on Gene Expression Levels of JAK2-STAT3, NF-κB, and SOCS3 in Cells Cultured from Biopsies of Mammary Lesions.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Cells, Cultured; Female; Gene Expression; Humans; In | 2015 |
Immunological consequences of immunization with tumor lysate vaccine and propranolol as an adjuvant: A study on cytokine profiles in breast tumor microenvironment.
Topics: Adjuvants, Immunologic; Animals; Breast Neoplasms; Cancer Vaccines; Cell Line, Tumor; Cytokines; Dis | 2017 |
Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models.
Topics: Animals; Antihypertensive Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell | 2017 |
Norepinephrine antagonists and cancer risk.
Topics: Atenolol; Breast Neoplasms; Clonidine; Colonic Neoplasms; Female; Humans; Lung Neoplasms; Male; Meto | 2011 |
Low-dose propranolol for infantile haemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Breast Neoplasms; Ear Neoplasms; Female; Follow-U | 2011 |
Beta-adrenergic signaling, a novel target for cancer therapy?
Topics: Adrenergic beta-Antagonists; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Female; Humans; Hyp | 2010 |
Expanding our therapeutic options: Beta blockers for breast cancer?
Topics: Adrenergic beta-Antagonists; Atenolol; Breast Neoplasms; Diabetes Complications; Disease-Free Surviv | 2011 |
Beta blockers and breast cancer mortality: a population- based study.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Breast Neoplasms; Disease Progression; Female; Humans; | 2011 |
Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineopla | 2011 |
Involvement of α2- and β2-adrenoceptors on breast cancer cell proliferation and tumour growth regulation.
Topics: Adrenergic Agonists; Adrenergic Antagonists; Albuterol; Animals; Antineoplastic Agents; Breast Neopl | 2012 |
Norepinephrine promotes the β1-integrin-mediated adhesion of MDA-MB-231 cells to vascular endothelium by the induction of a GROα release.
Topics: Adrenergic beta-Antagonists; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Chemokine CXCL1; End | 2012 |
[β-blockers: a new and emerging treatment for melanoma].
Topics: Adrenergic beta-Antagonists; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Evidenc | 2012 |
A retrospective in vitro study of the impact of anti-diabetics and cardioselective pharmaceuticals on breast cancer.
Topics: Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Blood Glucose; Breast Neoplasms; Cell Line, Tumo | 2012 |
Expression of inwardly rectifying potassium channels (GIRKs) and beta-adrenergic regulation of breast cancer cell lines.
Topics: Adenocarcinoma; Adrenergic beta-Antagonists; Breast Neoplasms; Female; G Protein-Coupled Inwardly-Re | 2004 |
A call for caution in the use of aminoglutethimide: negative interactions with dexamethasone and beta blocker treatment.
Topics: Adrenergic beta-Antagonists; Aged; Aminoglutethimide; Brain Neoplasms; Breast Neoplasms; Dexamethaso | 1984 |
Alpha2-adrenergic effect on human breast cancer MCF-7 cells.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Breast Neoplas | 1999 |
Pharmacological inhibition of phosphatidylcholine biosynthesis is associated with induction of phosphatidylinositol accumulation and cytolysis of neoplastic cell lines.
Topics: Adrenergic beta-Antagonists; Antineoplastic Agents; Breast Neoplasms; Cell Death; Cell Survival; Cho | 2000 |
Clinical importance of melatonin.
Topics: Adolescent; Adult; Aged; Amniotic Fluid; Breast Neoplasms; Child; Circadian Rhythm; Female; Humans; | 1979 |
Radical mastectomy in a patient with coexistent Graves' disease.
Topics: Adult; Breast Neoplasms; Carcinoma; Female; Graves Disease; Heart Sounds; Humans; Iodine Radioisotop | 1976 |